Get to know our clinical trials

Patients with metastatic breast cancer

THE MAIN OBJECTIVE OF THIS STUDY IS TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY (HOW WELL A DRUG WORKS) OF SAMURACICLIB IN COMBINATION WITH ELACESTRANT FOR THE TREATMENT OF HR AND HER2- BREAST CANCER.

Imagen de la Dra. Luisa Sánchez Lorenzo. Oncología Médica. Especialista en Radiología de la Clínica Universidad de Navarra en Madrid.
Dr. Luisa Sánchez Lorenzo Curriculum
Specialist Medical Oncology Department
Madrid headquarters
Cancer Center
Breast Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE IB/II OPEN-LABEL STUDY OF SAMURACICLIB IN COMBINATION WITH ELACESTRANT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC OR LOCALLY ADVANCED BREAST CANCER.
  • Code EudraCT: 2023-000072-35
  • Protocol number: CT7001-003
  • Promoter: Carrick Therapeutics
  • Molecule/Drug: Samuraciclib

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION